[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hidradenitis-suppurativa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hidradenitis-suppurativa":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,42,70,99,125,147,181,203,226,249,271,302,326,345,362,386,413,430,451,475,499,520,548,567,603],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100610283","phase-2-a-study-to-investigate-efficacy-and-safety-with-sar445399-in-adult-participants-with-moderate-to-severe-hidradenitis-suppurativa-100610283",false,"NCT07225569","A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","A Randomized, Double-blind, Placebo-controlled, Phase 2, Dose-finding Study to Investigate the Efficacy and Safety of SAR445399 in Participants With Moderate to Severe Hidradenitis Suppurativa","CLAROS","Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n* Participants with a history of signs and symptoms consistent with hidradenitis suppurativa (HS) for at least 6 months prior to Baseline\n* Participants must have HS lesions present in at least 2 distinct anatomic areas (eg, left, and right axilla; or left axilla and left inguino-crural fold), with at least 1 body site being Hurley Stage II or III.\n* Participant must have a total abscess and inflammatory nodule (AN) count of ≥5 at the Baseline Visit.\n* Participant must have had an inadequate response to a trial of an oral antibiotic for treatment of HS, exhibited recurrence after discontinuation of antibiotics or demonstrated intolerance to antibiotics or has a contraindication to oral antibiotics for treatment of their HS as assessed by the Investigator through participant interview and review of medical history.\n* Participants in the biologic-naïve stratum must be naïve to any prior use of biologic therapy with a potential impact on HS; Participants in the biologic-experienced stratum must have documented history of use of at least one dose of biologic therapy for HS.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with assessment of HS.\n* History of recurrent or recent serious infection\n* Known history of or suspected current immunosuppression\n* History of solid organ transplant or stem cell transplant.\n* History of splenectomy\n* History of malignancy or lymphoproliferative disease other than adequately treated or nonmetastatic squamous cell carcinoma of the skin that was excised and completely cured or nonmetastatic basal cell carcinoma of the skin that was excised and completely cured.\n* Any other medical condition or severe, concomitant illness, including psychiatric illness and substance abuse, that may present an unreasonable risk to the study participants, make participants unreliable or may interfere with study assessments\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","ALL","18 Years",{"count":21,"type":22},144,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This is a multinational, randomized, double-blind, placebo-controlled, Phase 2, dose finding study to evaluate the efficacy and safety of different doses of SAR445399 in adult participants with moderate to severe hidradenitis suppurativa.\n\nThe purpose of this study is to assess the efficacy and safety of two doses of SAR445399 compared with placebo in adult participants with moderate to severe hidradenitis suppurativa.\n\nThe study duration (per participant) will be up to 46 weeks with a total of 16 visits. The treatment duration will be 32 weeks which includes 16-week double-blinded initial treatment period and a 16-week treatment-blinded extension period.",[28],"Hidradenitis Suppurativa","RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-01","ACTUAL",{"date":35,"type":33},"2025-12-29",{"date":37,"type":22},"2027-12-01",{"name":39,"class":40},"Sanofi","INDUSTRY",66,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100614624","real-world-secukinumab-outcomes-in-canadian-hs-patients-100614624","NCT07282015","Real-world Secukinumab Outcomes in Canadian HS Patients","A Prospective Study to Describe the Real-world Treatment Outcomes in Canadian Patients With Moderate-to-severe Hidradenitis Suppurativa Treated With secukInumab (HS-RISE)","HS-RISE","Inclusion Criteria:\n\n1. Patients must give written, signed, and dated informed consent before any information is collected and any study-related activity is performed.\n2. Adult patients at the time of informed consent signature.\n3. Patients with the diagnosis of moderate-to-severe HS, as determined by the dermatologist.\n4. Patients who have been newly prescribed secukinumab as part of routine clinical care according to the approved Canadian PM. The decision to prescribe secukinumab must be made prior to,and independent of, study participation. First treatment with secukinumab must occur no more than 7 days (≤7 days) prior to Baseline visit.\n5. Patients who can understand written and spoken Canadian English or French.\n\nExclusion Criteria:\n\n1. Any medical or psychological condition in the treating physician's opinion that may prevent the patient from study participation.\n2. Patients who have any contraindications to treatment with secukinumab, as defined in the Canadian PM.\n3. Patients who have had any prior exposure to secukinumab (i.e., \\>7 days prior to the baseline visit).","100 Years",{"count":52,"type":22},142,"OBSERVATIONAL","The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.",[28],[28,57,58,59],"NIS","secukinumab","Phase IV","2026-06-19",{"date":62,"type":33},"2026-06-23",{"date":64,"type":33},"2025-12-12",{"date":66,"type":22},"2028-02-11",{"name":68,"class":40},"Novartis Pharmaceuticals",15,{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100644273","phase-3-an-extension-study-to-assess-safety-and-efficacy-of-remibrutinib-in-participants-with-moderate-to-severe-hs-100644273","NCT07665437","An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS","A Double-blind, Double-dummy, Parallel Group, Multicenter Phase 3 Extension Study Evaluating the Long-term Safety and Efficacy of 2 Doses of Remibrutinib in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","Key Inclusion Criteria:\n\n* Signed informed consent must be obtained before any assessment is performed.\n* Participant has completed the full study treatment period according to the protocol (68 weeks) in the core studies (CLOU064J12301 or CLOU064J12302).\n* Participant does not meet any treatment discontinuation criteria of the core study at Week 68.\n\nKey Exclusion Criteria:\n\n* Ongoing or planned use of prohibited HS or non-HS treatments.\n* Participants not expected to benefit from participation in the extension study or participants expected to be exposed to an undue safety risk if participating in the extension study, as assessed by the Investigator.\n* Current severe progressive or uncontrolled disease, which in the judgment of the Investigator renders the participant unsuitable for the study.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.",{"count":78,"type":22},710,[80],"PHASE3","The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of remibrutinib (LOU064) in adult participants with moderate to severe hidradenitis suppurativa (HS) who have completed either of the preceding Phase 3 studies, CLOU064J12301 or CLOU064J12302.",[28],[84,85,86,87,88,89],"BTK inhibitor","hidradenitis suppurativa","HiSCR","remibrutinib","Phase 3","extension study","NOT_YET_RECRUITING","2026-06-18",{"date":93,"type":33},"2026-06-24",{"date":95,"type":22},"2026-07-09",{"date":97,"type":22},"2031-10-27",{"name":68,"class":40},{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":18,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100586935","phase-3-a-study-to-assess-the-pharmacokinetics-and-safety-of-bimekizumab-in-children-and-adolescents-with-moderate-to-severe-hidradenitis-suppurativa-100586935","NCT06921850","A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa","A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa","Inclusion Criteria:\n\n* Study participant must be 12 to \\\u003C18 years of age at the time of informed consent\u002Fassent, at Tanner stage 2 or more, for the first 8 participants only, followed by also including participants ≥9 to \\\u003C18 years of age at Tanner stage 2 or more.\n* Study participant must have a diagnosis of HS for at least 6 months prior to the Baseline Visit.\n* Study participant must have moderate to severe HS, defined as a total of ≥5 inflammatory lesions (ie, the sum of abscesses and inflammatory nodules), as assessed at both the Screening and Baseline Visits.\n* Study participant must have HS lesions present in at least 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or III, as assessed at both the Screening and Baseline Visits.\n* Study participant must have had a history of inadequate response to a course of a systemic antibiotic for treatment of HS\n* Study participant must weigh ≥30kg at the Screening Visit.\n\nExclusion Criteria:\n\n* Study participant has a draining tunnel count of \\>20 at either the Screening or Baseline Visits.\n* Study participant has experienced primary failure (no response within 12 weeks) to 1 or more IL 17 biologic response modifiers (eg, brodalumab, ixekizumab, secukinumab) OR primary failure to more than 1 biologic response modifier other than an IL-17 biologic response modifier.\n* Study participant has previously participated in this study or has received previous therapy with bimekizumab.\n* Study participant has a history of IBD or symptoms suggestive of IBD.\n* History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated\n* Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections)\n* Study participant has received drugs outside the specified timeframes relative to the Baseline Visit or receives prohibited concomitant treatments\n* Study participant has the presence of active suicidal ideation, or positive suicide behavior,\n* Study participant diagnosed with severe depression in the past 6 months prior to the Screening Visit.\n* Study participant has a history of psychiatric inpatient hospitalization within the past year before enrolling into the study.","9 Years","17 Years",{"count":109,"type":22},40,[80],"The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)",[28],[114,115,28],"Bimekizumab","HS",{"date":117,"type":33},"2026-06-22",{"date":119,"type":33},"2025-04-07",{"date":121,"type":22},"2029-03-06",{"name":123,"class":40},"UCB Biopharma SRL",18,{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},"100606082","phase-2-brivekimig-for-the-treatment-of-moderate-to-severe-hidradenitis-suppurativa-100606082","NCT07170917","Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa","A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of Brivekimig Followed by a Maintenance Period in Participants With Moderate to Severe Hidradenitis Suppurativa","BRIGHTEN","Inclusion Criteria:\n\n* Participants with a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months prior to Baseline\n* Participants must have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla; or left axilla and left inguinocrural fold), one of which must be Hurley Stage II or Hurley Stage III.\n* Participant must have had an inadequate response to a trial of an oral antibiotic for treatment of HS, exhibited recurrence after discontinuation of antibiotics, demonstrated intolerance to antibiotics, or has a contraindication to oral antibiotics for treatment of their HS as assessed by the Investigator through participant interview and review of medical history.\n* Participants must be either biologic-naive or biologic-experienced.\n* Participant must have a total abscess and inflammatory nodule (AN) count of ≥5 at the Baseline visit.\n* Participant must have a draining tunnel count of ≤20 at the Baseline visit.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with assessment of HS\n* History of recurrent or recent serious infection\n* Known history of significant immunosuppression\n* History of solid organ transplant or stem cell transplant\n* History of splenectomy\n* History of moderate to severe congestive heart failure.\n* History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease\n* Participants with a history of malignancy or lymphoproliferative disease other than adequately treated or nonmetastatic squamous cell carcinoma of the skin that was excised and completely cured or nonmetastatic basal cell carcinoma of the skin that was excised and completely cured\n* History of any other condition which, in the opinion of the Investigator, would put the participant at risk by participation in the protocol\n* Active suicidality and therefore significant suicide risk, as judged by the Investigator\n* A history of an Adverse Event (AE) attributed to or related to anti-TNF therapy (examples include, but are not limited, to serum sickness or anaphylaxis) for an HS or non-HS indication that would contraindicate readministration of an anti-TNF class therapy\n* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study\n* History (within last 2 years prior to Baseline visit) of prescription drug or substance abuse, including alcohol, considered significant by the Investigator\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",{"count":134,"type":22},208,[25],"This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa.\n\nThe purpose of the main study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe HS.\n\nStudy details include:\n\nThe study duration (per participant) will be up to approximately 60 weeks for participants not transitioning into the long-term extension (LTE) study and will be up to approximately 52 weeks for participants transitioning into the LTE study.\n\nThe randomized treatment duration will be up to approximately 48 weeks.",[28],"2026-06-11",{"date":140,"type":33},"2026-06-12",{"date":142,"type":33},"2025-11-06",{"date":144,"type":22},"2028-04-27",{"name":39,"class":40},79,{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":155,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":180},"100562149","identification-of-cutaneous-and-blood-biomarkers-predictive-of-response-to-systemic-treatments-during-chronic-inflammatory-skin-diseases-100562149","NCT06599411","Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases","Identification Des Marqueurs Biologiques cutanés et Sanguins prédictifs de réponse Aux Traitements systémiques au Cours Des Maladies cutanées Inflammatoires Chroniques","ImmuneSkinBank","Inclusion Criteria:\n\nPatients:\n\n* Age\\>18 years\n* Informed consent signed by the patient\n* Diagnosis of moderate to severe chronic inflammatory skin disease (IGA score 3 or 4) including: atopic dermatitis, psoriasis, hidradenitis suppurativa, lichen planus, cutaneous lupus, dermatomyositis, cutaneous scleroderma (=morphea), neutrophilic dermatosis, cutaneous granulomatosis, cutaneaous vasculitis, autoimmune bullous dermatosis\n* Or diagnosis of active leprosy (tuberculoid, lepromatous, reversion type 1, reversion type 2, hypersensitivity type 3), excluding pure neurological leprosy. Classification into 5 stages according to the Ridley and Jopling classification \\[1\\], Reversion reaction (type 1 reaction) and leprous erythema nodosum (type 2 reaction).\n\nHealthy controls :\n\n* Age\\>18 years\n* Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants\n* Informed consent signed by the patient\n* Absence of known cutaneous inflammatory disease.\n\nExclusion Criteria:\n\n* Under guardianship or curatorship\n* Pregnant or breastfeeding woman\n* Lack of affiliation with a social security system\n* Current systemic treatment with immunosupressant (including corticosteroid therapy) or an immunomodulator or received within the last 3 months.",true,{"count":157,"type":22},830,"Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable. The discovery of prognosis factors will help to precisely guide the treatment regimen and its intensification based on individual markers. The identification of new therapeutic targets is essential to develop new innovative treatments for inflammatory skin diseases.\n\nThe main objective is to identify new cellular or molecular prognostic factors associated with treatment response at 1 year in inflammatory skin diseases.\n\nThe secondary objectives are a better understanding of the pathophysiology of chronic inflammatory skin diseases, the identification of new cellular, molecular and microbiological prognostic factors associated with the clinical state after 10 years of evolution and the identification of prognostic markers of drug toxicity.",[160,161,28,162,163,164,165,166,167,168,169,170],"Atopic Dermatitis","Psoriasis","Lichen Planus","Cutaneous Lupus","Dermatomyositis","Cutaneaous Scleroderma","Neutrophilic Dermatosis","Cutaneous Granulomatosis","Active Leprosy","Autoimmune Bullous Dermatosis","Cutaneous Vasculitis","2026-06-10",{"date":140,"type":33},{"date":174,"type":33},"2025-10-20",{"date":176,"type":22},"2045-10-20",{"name":178,"class":179},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":180},"100541178","early-phase-1-evaluate-the-safety-and-efficacy-of-subcutaneous-siplizumab-in-the-treatment-of-hidradenitis-suppurativa-100541178","NCT06326476","Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.","An Open-label Parallel Group Pilot Study to Demonstrate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa","Inclusion Criteria:\n\n* Male or Female at least 18 years of age, and provide informed consent prior to study procedures.\n* Have moderate to severe HS classified as Hurley stage II or III for at least 6 months refractory to conventional therapies with a total AN count of greater than or equal to 5 prior to enrollment\u002Frandomization\n* Failed at least 1 course of oral antibiotics for treatment of HS (or demonstrated intolerance to, or had a contraindication to oral antibiotics for treatment of their HS).\n* Women of Childbearing potential must have a urine pregnancy test at screening, wk 0 and prior to administration of the study medication\n* Women of childbearing potential must be willing to continue a highly effective method of birth control throughout the study (oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system; barrier methods: condom or occlusive cap (diaphragm or cervical\u002Fvault caps) plus spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository (if available in their locale); male partner sterilization (the vasectomized partner should be the sole partner for that participant); true abstinence (when this is in line with the preferred and usual lifestyle of the participant).\n* Negative screening for tuberculosis (TB) (Quantiferon Gold, T-spot) within 3 months prior to screening\n* If a positive history of latent tuberculosis:\n\n  * Currently receiving treatment for latent TB per standard of care\n  * Have documentation of having completed treatment within 5 years prior to baseline\n* Agree not to have a live vaccination during the study.\n\nExclusion Criteria:\n\n* Any other active skin disease that in the opinion of the investigator would interfere with the assessment of HS\n* Have greater than 20 draining fistulas at screening or Day 1 prior to enrollment\u002Frandomization\n* Receipt of non-biologic treatments for HS within 4 weeks prior to baseline other than antibiotics or hormonal therapy\n* Receipt of biologic agents within 3 months prior to baseline\n* Receipt of any other investigational product within 3 months prior to baseline\n* Receipt of new oral antibiotics or hormonal therapy within 6 weeks prior to baseline.\n\n  * Subjects may be included if they are on steady dose of doxycycline or tetracycline antibiotics only for at least 6 weeks prior to baseline visit and may not change or discontinue dose during course of study.\n* Receipt of intralesional kenalog injections within 2 weeks prior to baseline\n* Any uncontrolled diagnosis or condition that in the opinion of the investigator will interfere with the assessments or the study.\n* Currently has a malignancy or a history of a malignancy within 5 years before screen (except successfully treated non-melanoma skin cancer or cervical carcinoma in situ)\n* History of an ongoing, chronic or recurrent infectious disease\n* Are currently pregnant, breastfeeding, or planning to get pregnant during the study.\n* Previous hypersensitivity reaction to siplizumab or to any of the components\n* Known infection with HIV, hepatitis B or hepatitis C at screening or randomization.\n\nPatients who are Hepatitis B Core antibody and\u002For Hep B Surface Antigen positive will be excluded from this study. Patients who are Hepatitis C ab positive will also be excluded from this study.\n\n* Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the subject and\u002For places the subject at unacceptable risk for receiving an immunomodulatory therapy.\n* Any of the following laboratory abnormalities within 30 days of enrollment:\n\n  * White blood count (WBC) \\\u003C 3 x 103\u002FμL;,\n  * CD4+ count below the lower limit of normal,\n  * Platelet count \\\u003C 150,000 \u002FμL,\n  * Hemoglobin \\\u003C 10 g\u002FdL,\n  * ALT ≥ 2x upper limit of normal (ULN) or\n  * AST ≥ 2x ULN\n  * Serum creatinine \\>1.5x ULN in adults.\n  * Positive molecular testing of SARS-CoV-2\n  * ALC less than 800 lymphocytes\u002Fmm3",{"count":189,"type":22},12,[191],"EARLY_PHASE1","This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.",[28],"2026-05-28",{"date":196,"type":33},"2026-06-01",{"date":198,"type":33},"2025-05-09",{"date":200,"type":22},"2028-07-31",{"name":202,"class":179},"University of Alabama at Birmingham",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":4},"100627919","a-real-world-study-of-patients-with-hidradenitis-suppurativa-and-high-cardiovascular-risk-or-established-coronary-plaque-treated-with-secukinumab-100627919","NCT07454889","A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab","12 Months-observation of Patients Treated for Hidradenitis Suppurativa, With High Cardiovascular Risk or Established Coronary Plaque: A Prospective Monocentric Study - the HOPE Study","HOPE","Inclusion criteria:\n\n1. Adult participants aged ≥18 and ≤75 years.\n2. Diagnosis of moderate-to-severe HS (International Hidradenitis Suppurativa Severity Score System \\[IHS4\\] ≥4).\n3. Taking or planning to take secukinumab according to standard of care.\n4. Participants eligible for coronary imaging by Photon-Counting Computed Tomography (PCCT) based on at least one of the following:\n\n   1. Evidence of coronary atherosclerotic plaque previously identified by imaging and receipt of stable, guideline-directed medical therapy.\n   2. Clinical indication as determined by a cardiologist.\n   3. Very high risk of developing cardiovascular diseases according to the Systematic Coronary Risk Evaluation 2 (SCORE2) and Systematic Coronary Risk Evaluation 2 - Older Persons (SCORE2-OP) risk models for moderate risk European regions (score ≥7.5% for participants \\\u003C50 years old, score ≥10% for participants 50-69 years old, and score ≥15% for participants ≥70 years old).\n5. Signed Informed Consent Form (ICF), obtained from the participant or a legally authorized representative, prior to any study-related activities.\n\nExclusion criteria:\n\n1. Known history of previous Myocardial Infarction (MI), Acute Coronary Syndromes (ACS) or Transient Ischemic Attack (TIA) requiring urgent intervention\u002Fhospitalization in the last 6 months prior to enrollment.\n2. Use of investigational cardiovascular or anti-inflammatory drugs.\n3. Use of any other investigational drugs.\n4. Chronic Kidney Disease (estimated Glomerular Filtration Rate \\[eGFR\\] \\\u003C30 mL\u002Fmin).\n5. Contraindications to perform PCCT (including allergies to contrast).\n6. Other autoimmune systemic diseases or active neoplastic diseases.\n7. Known history of Moderate to severe anemia.\n8. Congestive Heart Failure (New York Heart Association \\[NYHA\\] Class III-IV).\n9. Pregnant or lactating women.","75 Years",{"count":213,"type":22},34,"The aim of this study is to assess the real-world effects of secukinumab in adult participants with moderate-to-severe Hidradenitis Suppurativa (HS), particularly focusing on its potential impact on coronary atherosclerotic plaque progression or stability. Participants will be enrolled at a single dermatology and cardiology center in Italy and will receive secukinumab as part of their routine clinical care",[28],[217,218],"Coronary Plaque","Cardiovascular Risk","2026-05-27",{"date":194,"type":33},{"date":222,"type":22},"2026-05-31",{"date":224,"type":22},"2027-03-31",{"name":68,"class":40},{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":234,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":248},"100634725","long-term-observational-study-to-collect-in-a-real-world-population-data-on-the-treatment-pattern-of-secukinumab-in-adult-patients-with-moderate-to-severe-hs-within-the-italian-population-100634725","NCT07543419","Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population","Long Term Observational, Prospective, Multicenter Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) Within the Italian Population (ANIMA - Italy)","ANIMA - Italy","Inclusion Criteria:\n\nStudy participants eligible for inclusion in this study must meet all the following criteria:\n\n1\\. Male and Female patients who provide written informed consent and privacy form (ICF\\&PF) to participate in the study.\n\n2\\. Aged ≥ 18 years at ICF\\&PF signature. 3. Patients with moderate or severe HS (IHS4 and\u002For Hurley staging system, as assessed by the investigators) at index date.\n\n4\\. The start of secukinumab is within 30 days after the ICF\\&PF signature (enrolment), as per local standard clinical practice. Patients were not treated with secukinumab before enrolment within the Managed Access Program (MAP). The initiation of secukinumab is based on dermatologist's own practice, regardless of study participation.\n\nFor HRU and economic burden only:\n\n5\\. Patients who provide written ICF\\&PF to allow the use of secondary (administrative) data for the purposes of this study.\n\n6\\. Patients with more than 12 months of residence inside the area of competence of the LHU (applicable only to study sites associated with the 6 LHUs).\n\nExclusion Criteria:\n\nStudy participants meeting any of the following criteria are not eligible for inclusion in this study:\n\n7\\. Participation in an ongoing clinical trial. 8. Any medical or psychological condition that may prevent study participation, based on practitioners' decision-making.\n\nFor HRU and economic burden only:\n\n9\\. Patients will be excluded if the unique identifier does not allow them to be identified in the LHU administrative databases related to the site where they were enrolled.",{"count":235,"type":22},250,"The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on secukinumab, healthcare resource utilization and the economic impact of HS in Italy.",[28],[28,115,58,57,239],"LHUs","2026-05-19",{"date":242,"type":33},"2026-05-22",{"date":244,"type":33},"2025-12-17",{"date":246,"type":22},"2028-09-30",{"name":68,"class":40},11,{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":180},"100604624","phase-2-a-study-of-lad191-in-adults-with-hidradenitis-suppurativa-100604624","NCT07151937","A Study of LAD191 in Adults With Hidradenitis Suppurativa","A Seamless Phase 2a\u002F2b, Randomized, Double-Blind, Placebo- and Active-Controlled, Multiple-Arm, Multiple-Stage, Adaptive Study Evaluating the Efficacy and Safety of LAD191 in Adults With Moderate-to-Severe Hidradenitis Suppurativa","Inclusion Criteria:\n\n* Aged greater than or equal to (\\>=) 18 to less than or equal to (\\\u003C=) 65 years.\n* A diagnosis of moderate-to-severe HS defined as a total of \\>= 5 inflammatory lesions (i.e., number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline\u002FDay 1 visits, with signs and symptoms of HS for at least 6 months.\n* HS lesions present in at least 2 distinct anatomic areas (e.g., left and right axilla), one of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline\u002FDay 1 visits.\n* History of inadequate response, intolerance, or contraindication to a course of a systemic antibiotics for treatment of HS at the screening visit.\n* Regular use of over-the-counter topical antiseptics on HS lesions and agrees to regular use, throughout the entirety of the study.\n* Participants who are women of child-bearing potential (WOBCP) and male participants must agree to the requirements for the avoidance of pregnancy and exposure of the participant's partner to LAD191 during the study.\n\nExclusion Criteria:\n\n* HS with \\>20 draining tunnels at the Screening or Baseline\u002FDay 1 visit.\n* Ongoing medical conditions requiring systemic immunosuppressive\u002Fimmunomodulating treatments during the study.\n* Known hypersensitivity to LAD191 or any of its excipients.\n* Known hypersensitivity to adalimumab or biosimilar or any of its excipients or meeting any warning or contraindication to adalimumab treatment as per the approved product information, and as per the Investigator's judgment.\n* Hypersensitivity or systemic reaction to a prior biologic (antibody-based) therapy, regardless of indication, that was clinically significant, as per the Investigator's judgment.\n* Prior treatment with LAD191.\n* Live or attenuated vaccinations 4 weeks prior to Baseline\u002FDay 1 or is planning to receive any such vaccine during the study.\n* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\n* Intention to use any concomitant medication or therapy that is not permitted by this protocol or failure to meet the required washout period for a particular prohibited medication prior to Baseline\u002FDay 1.","65 Years",{"count":258,"type":22},200,[25],"The main purpose of this study is to assess the efficacy of multiple dosing regimens of LAD191 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS) and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.",[28],"2026-05-07",{"date":264,"type":33},"2026-05-11",{"date":266,"type":33},"2025-11-05",{"date":268,"type":22},"2027-11-25",{"name":270,"class":40},"Almirall, S.A.",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":279,"minAge":19,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":23,"phases":282,"briefSummary":284,"conditions":285,"keywords":289,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":299,"leadSponsor":301,"locationsCount":189},"100584350","phase-1-a-study-to-assess-the-concentration-of-bimekizumab-in-mature-breast-milk-from-mothers-receiving-treatment-with-bimzelx-bimekizumab-100584350","NCT06888193","A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)","A Multicenter Open-label, Prospective Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)","BE CARING","Inclusion Criteria:\n\n* Study participant must be at least 18 years of age at the time of signing the informed consent.\n* Study participant is being treated with commercial bimekizumab per locally approved prescribing information and in accordance with her treating physician.\n* Study participant is breastfeeding and intends to breastfeed throughout the Sampling Period.\n* The decision to treat with bimekizumab and to breastfeed is made independently from and prior to the study participant consenting to participate in the study.\n* Study participant must be on bimekizumab treatment for at least 12 weeks after delivery and since starting\u002Frestarting\u002Fcontinuing bimekizumab prior to sampling (prior to start of the Sampling Period).\n* A female study participant is eligible to participate if she is not pregnant and does not plan to become pregnant during the study.\n\nExclusion Criteria:\n\n* Study participant has any medical, obstetrical, or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study.\n* The infant has any abnormality noted on physical examination or medical history that, in the opinion of the Investigator, may jeopardize or compromise study participation.\n* Study participant has a history of chronic alcohol or drug abuse within the previous last year.\n* Study participant has history of breast implants, breast augmentation, or breast reduction surgery.\n* Study participant plans a surgical intervention during the Screening Period and Sampling Period or anticipates having surgery while participating in the Sampling Period (does not apply to tubal ligation).\n* Study participant or her infant has participated in another study of an investigational medicinal product (IMP) (and\u002For an investigational device) within the previous 6 months or is currently participating in another study of an IMP (and\u002For an investigational device), unless the study is UCB PS0036 or a bimekizumab registry study.\n* Study participant or her infant has previously participated (ie, entered the sampling period) in this study.","FEMALE",{"count":281,"type":22},20,[283],"PHASE1","Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.",[286,287,288,28],"Moderate to Severe Plaque Psoriasis","Psoriatic Arthritis","Axial Spondyloarthritis",[114,290,291,292,115,293,294],"Breastfeeding mothers","Bimzelx®","PSO","AxSpa","PsA","2026-04-30",{"date":297,"type":33},"2026-05-01",{"date":266,"type":33},{"date":300,"type":22},"2027-05-03",{"name":123,"class":40},{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":211,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":312,"conditions":313,"keywords":314,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":325},"100610500","phase-2-a-16-week-study-to-learn-about-the-study-medicine-called-ritlecitinib-in-adults-with-long-lasting-painful-red-skin-lumps-known-by-the-medical-term-hidradenitis-suppurativa-or-hs-100610500","NCT07228390","A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.","A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF RITLECITINIB (PF-06651600) IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA","Key Eligibility Criteria:\n\nInclusion Criteria:\n\n1. Male or female participants ≥18 to ≤75 years of age.\n2. Participants with a diagnosis (based on clinical history and physical examination) of moderate to severe HS for at least 6 months prior to Screening Visit and inadequate response to at least 4-week (28 days) treatment with oral antibiotics for the treatment of HS.\n\nExclusion Criteria:\n\n1. Presence of ≥20 draining fistulae at Screening or BL visit\n2. Evidence of other active skin disease or condition at screening\n3. Have a known immunodeficiency disorder\n4. Having a history of systemic infection requiring hospitalization or parenteral therapy, including history of infection with Mycobacterium TB\n5. Specific Viral Infection History (incl. history of herpes zoster, HBV or HCV Infection\n6. Current or recent history of clinically significant severe, progressive, or uncontrolled other medical conditions\n7. Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years",{"count":310,"type":22},240,[25],"The purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidradenitis suppurativa (HS). HS is a disease causing long lasting painful red skin lumps.\n\nThis study is seeking participants who:\n\n* have moderate or severe HS\n* have previously received antibiotics for HS that did not help, or could not tolerate antibiotics Participants will be randomly (like a flip of coin) assigned to receive either the study medicine or a placebo (a pill that looks like the study medicine but does not contain any medicine). The study medicine or placebo will be taken by mouth once daily at home. For the first part of the study, participants will receive a loading (starting) dose. For the next part of the study, participants will receive a maintenance (ongoing) dose.\n\nParticipants will take part in the study for about 24 weeks (about 6 months). There will be about 10 study clinic visits: a screening visit, Day 1, and then every 1, 2, or 4 weeks until week 16. At each visit, participants will report on their health and have tests such as physical exams, blood and urine tests, vital signs, chest X-rays, ECGs, hearing tests, and questionnaires. Participants will record when they take the study medicine and their HS symptoms every day in an eDiary on a mobile phone.\n\nThe experiences of participants receiving the study medicine will be compared to those receiving placebo to help see if the study medicine is safe and effective.",[28],[315],"Ritlecitinib","2026-04-28",{"date":318,"type":33},"2026-04-29",{"date":320,"type":33},"2025-11-13",{"date":322,"type":22},"2027-04-02",{"name":324,"class":40},"Pfizer",54,{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":18,"minAge":333,"maxAge":4,"enrollmentInfo":334,"targetDuration":333,"studyType":53,"phases":4,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":338,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":180},"100371376","hidradenitis-suppurativa-prospective-observational-registry-and-biospecimen-repository-100371376","NCT04115566","Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository","HS PROGRESS","Inclusion Criteria:\n\n1. Male or female ≥ 10 years of age\n2. Diagnosis of HS by a dermatologist or practitioner experienced in making a diagnosis of HS\n3. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n1\\. Inability to give informed consent or unavailability of a parent\u002Fguardian who is able and willing to give informed consent.","10 Years",{"count":335,"type":22},3000,"Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.",[28],{"date":318,"type":33},{"date":340,"type":33},"2020-08-01",{"date":342,"type":22},"2035-05-01",{"name":344,"class":179},"University of California, San Francisco",{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":155,"sex":18,"minAge":351,"maxAge":4,"enrollmentInfo":352,"targetDuration":333,"studyType":53,"phases":4,"briefSummary":336,"conditions":354,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":180},"100360015","clinical-and-biological-characteristics-of-hidradenitis-suppurativa-100360015","NCT03967600","Clinical and Biological Characteristics of Hidradenitis Suppurativa","Hidradenitis Suppurativa Patients\n\nInclusion Criteria:\n\n1. Age 13 years or older\n2. Diagnosis of HS clinically-confirmed by a physician\n\nExclusion Criteria:\n\n1\\. Inability to give informed consent or have a parent\u002Fguardian who is able and willing to give informed consent.\n\nHealthy Volunteer\n\nInclusion Criteria:\n\n1. No history of chronic skin conditions\n2. No recent history of antibiotic use\n\nExclusion Criteria:\n\n1\\. Inability to give informed consent or have a parent\u002Fguardian who is able and willing to give informed consent.","13 Years",{"count":353,"type":22},1000,[28],{"date":356,"type":33},"2026-05-04",{"date":358,"type":33},"2016-07-15",{"date":360,"type":22},"2026-07-15",{"name":344,"class":179},{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":256,"enrollmentInfo":369,"targetDuration":4,"studyType":23,"phases":371,"briefSummary":372,"conditions":373,"keywords":374,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":4},"100635063","phase-2-a-proof-of-concept-study-of-lad328-in-adults-with-hidradenitis-suppurativa-100635063","NCT07547813","A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa","A Phase 2, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate Efficacy and Safety of LAD328 in Adult Subjects With Moderate-to-Severe Hidradenitis Suppurativa","Inclusion Criteria:\n\n* Male or female between 18 and 65 years old inclusive.\n* A diagnosis of moderate-to-severe HS defined as a total of \\>=5 inflammatory lesions (i.e., number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline visits, with a clinical history of HS for at least 6 months.\n* HS lesions present in at least 2 distinct anatomic areas (e.g., left and right axilla), one of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline visits.\n* History of inadequate response, or intolerance or contraindication, to a course of a systemic antibiotics for treatment of HS at the Screening visit.\n* Agree to regularly use, over-the-counter topical antiseptics on their HS lesions throughout the entirety of the study.\n* Participants who are woman of child-bearing potential (WOCBP) and male participants must agree to the requirements for the avoidance of pregnancy and exposure of the participant's partner to LAD328 during the trial.\n\nExclusion Criteria:\n\n* HS with \\>20 draining tunnels either at the Screening or Baseline visits.\n* Ongoing medical conditions (e.g., inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus and sarcoidosis) requiring systemic immunosuppressive\u002Fimmunomodulating treatments (e.g., methotrexate, ciclosporin, corticosteroids, cytokine-targeted therapy and JAK inhibitors) during the trial.\n* Known or suspected hypersensitivity to trial product or any of its excipients.\n* Hypersensitivity or systemic reaction to a prior biologic (antibody-based) therapy (regardless of indication), that was clinically significant, as per judgment of Investigator.\n* Prior treatment with LAD328.\n* Live and attenuated vaccinations 4 weeks prior Pre-treatment or is planning to receive any such vaccine during the trial.\n* Females who are pregnant or breast-feeding or seeking to become pregnant during the trial.",{"count":370,"type":22},50,[25],"The main purpose of this study is to evaluate the effect of LAD328 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS), and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.",[28],[375,376,377],"Hidradenitis","Skin Diseases","Infections","2026-04-17",{"date":380,"type":33},"2026-04-23",{"date":382,"type":22},"2026-04",{"date":384,"type":22},"2027-04",{"name":270,"class":40},{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":18,"minAge":393,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":23,"phases":396,"briefSummary":397,"conditions":398,"keywords":399,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":412},"100589808","phase-3-study-to-evaluate-the-efficacy-and-safety-of-ruxolitinib-cream-in-participants-with-hidradenitis-suppurativa-true-hs1-100589808","NCT06959225","Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)","A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa","Inclusion Criteria:\n\n* Diagnosis of HS for at least 6 months prior to screening visit.\n* Mild to moderate HS (Hurley I or II) with the following at both screening and baseline visits:\n\n  * A total AN count of at least 4, with no draining tunnels AND\n  * Affecting at least 2 distinct anatomical areas\n* Agreement to NOT use topical and systemic antibiotics for treatment of HS during the vehicle-controlled period.\n* Agreement to NOT use topical antiseptics, including washes and leave-on products on the areas affected by HS lesions during the vehicle-controlled period and Weeks 16 to 20 of the extension period.\n* Further inclusion criteria apply.\n\nExclusion Criteria:\n\n* Body surface areas to be treated exceed 20% BSA at screening or baseline\n* Presence of draining tunnels at screening or baseline.\n* Medical history including current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.\n* Laboratory values outside of the protocol-defined criteria.\n* Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.\n* Further exclusion criteria apply.","12 Years",{"count":395,"type":22},550,[80],"The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.",[28],[400,401,402],"Hidradenitis suppurativa","skin disease","ruxolitinb cream","2026-04-15",{"date":405,"type":33},"2026-04-16",{"date":407,"type":33},"2025-06-23",{"date":409,"type":22},"2027-07-11",{"name":411,"class":40},"Incyte Corporation",101,{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":18,"minAge":393,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":397,"conditions":420,"keywords":421,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":428,"locationsCount":429},"100589730","phase-3-study-to-evaluate-the-efficacy-and-safety-of-ruxolitinib-cream-in-participants-with-hidradenitis-suppurativa-true-hs2-100589730","NCT06958211","Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)",{"count":395,"type":22},[80],[28],[400,401,402],"2026-04-07",{"date":424,"type":33},"2026-04-08",{"date":426,"type":33},"2025-06-12",{"date":409,"type":22},{"name":411,"class":40},107,{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":18,"minAge":393,"maxAge":211,"enrollmentInfo":437,"targetDuration":4,"studyType":23,"phases":439,"briefSummary":440,"conditions":441,"keywords":442,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":438},"100596753","phase-1-study-to-evaluate-the-maximal-use-of-ruxolitinib-cream-in-adult-and-adolescent-participants-with-hidradenitis-suppurativa-100596753","NCT07049575","Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa","A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa","Inclusion Criteria:\n\n* Diagnosis of HS for at least 6 months before screening visit.\n* Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits.\n* Total estimated treatment BSA \\> 20% at screening and baseline.\n* Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period.\n* Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.\n* Further inclusion criteria apply.\n\nExclusion Criteria:\n\n* Current or history of skin condition(s) other than HS that might confound the evaluation of HS; clinically uncontrolled cardiovascular disease; thrombosis; certain cancers; certain infections; severe anemia, thrombocytopenia, or neutropenia; other medical conditions at the discretion of the investigator.\n* Laboratory values outside of the protocol-defined ranges.\n* Further exclusion criteria apply.",{"count":438,"type":22},24,[283],"The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.",[28],[400,401,402],"2026-04-02",{"date":445,"type":33},"2026-04-06",{"date":447,"type":33},"2025-11-03",{"date":449,"type":22},"2026-12-09",{"name":411,"class":40},{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":155,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":180},"100515705","collection-of-samples-from-subjects-with-various-skin-conditions-and-healthy-volunteers-100515705","NCT05994976","Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers","Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers for Molecular Characterization of Inflammatory Skin Diseases","Inclusion Criteria:\n\nAll subjects:\n\n1. Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.\n2. Subject must be willing to comply with all study procedures and must be available for the duration of the study.\n\n   Healthy volunteers:\n3. Male or female subject aged 18 years or older, at the time of consent.\n4. Subject is in good general health, according to the investigator's judgment.\n\n   Subjects with Acne:\n5. Male or female subject aged 18 to 45 years old, inclusive, at the time of consent.\n\n   Subjects with AD:\n6. Male or female subject aged 18 years or older, at the time of consent.\n7. Subject has clinically confirmed diagnosis of active AD, according to Hanifin and Rajka criteria.\n\n   Subjects with CHE:\n8. Male or female subject aged 18 years or older, at the time of consent.\n9. Subject has at least a 6-month history of CHE before Screening (information obtained from medical chart or subject's physician, or directly from the subject).\n\n   Subjects with HS:\n10. Male or female subject aged 18 years or older, at the time of consent.\n11. Subject has a clinically confirmed diagnosis of active HS with a disease duration of ≥ 6 months before screening as determined by the investigator through subject interview and\u002For review of the medical history.\n\n    Subjects with PPP:\n12. Male or female subject aged 18 years or older at the time of consent.\n13. Subject has at least a 6-month history of PPP as defined by the presence of pustules on palms and\u002For soles, but without evidence of infection on palms and soles (information obtained from medical chart or subject's physician, or directly from the subject).\n\n    Subjects with psoriasis:\n14. Male or female subject aged 18 years or older, at the time of consent.\n\nExclusion Criteria:\n\nAll subjects:\n\n1. Subject is a female who is pregnant or who is planning to become pregnant during the study.\n2. Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.",{"count":459,"type":22},500,"The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.",[462,160,463,28,464,465],"Acne","Chronic Hand Eczema","Plaque Psoriasis","Palmoplantar Pustulosis","2026-03-25",{"date":468,"type":33},"2026-03-30",{"date":470,"type":33},"2023-10-17",{"date":472,"type":22},"2028-08",{"name":474,"class":179},"Innovaderm Research Inc.",{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":23,"phases":484,"briefSummary":485,"conditions":486,"keywords":487,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":498},"100611721","phase-2-a-study-of-zasocitinib-in-adults-with-hidradenitis-suppurativa-100611721","NCT07244263","A Study of Zasocitinib in Adults With Hidradenitis Suppurativa","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa","Inclusion Criteria:\n\nParticipant Willingness:\n\n1. Participant is willing and able to understand and fully comply with all trial procedures and requirements (including the use of digital tools and applications), in the opinion of the investigator.\n2. Participant has provided written informed consent and any required privacy authorization before the initiation of any trial procedures.\n\n   Disease Characteristics:\n3. Participants must have signs and symptoms of hidradenitis suppurativa (HS) for at least 6 months prior to screening, and a diagnosis of HS (confirmed by a dermatologist) at the screening visit with stable HS signs and symptoms for 2 months before screening, as determined by the investigator through interview or medical history.\n4. Participants should have HS lesions in at least 2 distinct anatomical areas, one of which must be at least Hurley Stage II or III at both screening and Day 1.\n5. Participants must have a total of greater than or equal to (\\>=) 5 inflammatory lesions (that is, number of abscesses plus number of inflammatory nodules) at both screening and Day 1.\n6. Participants must have a history of inadequate response to a previous course of oral antibiotic for treatment of HS or exhibited recurrence, intolerance, or contraindication during that course of oral antibiotic, as assessed by the principal investigator.\n\n   Age and Reproductive Status:\n7. Participant is aged \\>=18 years at the time of consent. In the European Union (EU)\u002FEuropean Economic Area (EEA), for participants aged 65 years or older, the investigator must document a favorable benefit-risk assessment to justify the participant's inclusion in the trial.\n8. Participant meets the following birth control requirement:\n\n   1. An individual with potential for pregnancy, who is now surgically sterile; OR\n   2. An individual of nonchildbearing potential with laboratory confirmation of postmenopausal status; OR\n   3. If sexually active with a nonsterilized individual who produces sperm, an individual with potential for pregnancy who agrees to use a highly effective method of contraception from the signing of informed consent throughout the duration of the trial.\n\n   The use of effective contraception will be required for participants assigned male sex at birth.\n\n   In the EU\u002FEEA, for participants who elect to use hormonal contraception as a form of highly effective contraception, the investigator must document a favorable benefit-risk assessment to justify the participant's inclusion in the trial at screening and every 3 months during the trial.\n9. For participants in the EU\u002FEEA, the investigator must have no reason to believe that the participant would be placed at risk by participating in the trial with regard to the European Commission decision as of 10 March 2023 on measures to minimize risk of serious side effects with JAK inhibitors (EMA\u002F142279\u002F2023) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) guideline on Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality as of 26 April 2023.\n\nExclusion Criteria:\n\nTarget Disease-Related Exclusions:\n\n1. Participant has a draining tunnel count of greater than (\\>) 20 at screening or Day 1.\n2. Participant has any other active skin disease or condition (for example, bacterial cellulitis, Candida intertrigo, extensive condyloma) that may, in the opinion of the investigator, interfere with the assessment of HS or participant has developed a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the trial assessments.\n3. Participant has a diagnosis of sarcoidosis, systemic lupus erythematosus, or active inflammatory bowel disease.\n4. Participant has a diagnosis of inflammatory conditions other than HS, including but not limited to, psoriasis, psoriatic arthritis, and rheumatoid arthritis.\n\n   Recent\u002FConcurrent Infectious Disease Exclusions:\n5. Tuberculosis (TB):\n\n   1. Participants have a history of active TB infection, regardless of treatment status.\n   2. Participants have signs or symptoms of active TB (including, but not limited to, chronic fever, chronic productive cough, night sweats, or weight loss) as judged by the investigator.\n   3. Participants have evidence of latent tuberculosis infection (LTBI) as evidenced by a positive QuantiFERON (QFT) result OR 2 indeterminate QFT results, and participant does not have documentation of appropriate LTBI prophylaxis or is not able or not willing to initiate appropriate LTBI prophylaxis. Participant remains eligible if there are no signs\u002Fsymptoms of active TB AND documentation of no history of active TB can be provided AND (1) participant can provide documentation of prior and complete treatment for LTBI (appropriate in duration and type per current local country guidelines) or (2) participant has a positive QFT result or 2 indeterminate QFT results but has initiated prophylaxis (appropriate in duration and type per current local guidelines) a minimum of 2 weeks prior to Day 1. In the EU\u002FEEA, participants with evidence of LTBI, regardless of prophylaxis treatment status, must receive approval to participate in the trial from an infectious disease or other TB specialist (for example, pulmonologist).\n\n      Note: TB prophylaxis regimens should be administered according to local guidelines; however, because of potential interactions with zasocitinib, rifampin should not be used. For isoniazid monotherapy, a minimum of 6 months should be used. TB testing should be conducted using QFT-TB Gold submitted to the central laboratory unless alternate or additional tests are required per local guidelines.\n   4. Participant has had any imaging trial during or 6 months prior to screening, including x-ray, chest computed tomography, magnetic resonance imaging, or other chest imaging suggesting evidence of current active or a history of active TB. X-ray is required for all participants regardless of QFT-TB Gold results unless the participant has had normal chest imaging in the 6 months prior to screening.\n6. Herpes infections:\n\n   1. Participant has active herpes virus infection, including herpes zoster or herpes simplex 1 and 2 (demonstrated on physical examination and\u002For medical history) at screening or Day 1.\n   2. Participant has history of serious herpetic infection that includes any episode of disseminated disease, multidermatomal herpes zoster, herpes encephalitis, ophthalmic herpes, or recurrent herpes zoster (defined as 2 episodes within 2 years).\n7. Nonherpetic viral diseases:\n\n   1. Participant has presence of hepatitis C virus (HCV) antibody and a positive confirmatory test result for HCV RNA (nucleic acid test or polymerase chain reaction \\[PCR\\]). In the EU\u002FEEA, if the participant has total anti-HCV antibody positivity at screening but is confirmed to have no detectable HCV RNA by PCR testing, HCV RNA PCR testing will be assessed every 3 months until end of trial (EOT).\n   2. Participant has presence of positive hepatitis B virus surface antigen (HBsAg), or indeterminate HBsAg, presence of HBV DNA (regardless of serology), or positive anti-hepatitis B core antibody (HBcAb) without concurrent positive HBsAb (HBcAb+ and HBsAb-). In the EU\u002FEEA, if the participant has total anti-HBc antibody positivity at screening but is confirmed to have no detectable HBV DNA by PCR testing, the participant will repeat HBV DNA PCR testing every 3 months until the EOT; if a participant has anti-HBsAb positivity at screening but is confirmed to have no detectable HBV DNA by PCR testing, unless the participant has documented completion of the HBV vaccination series by medical history, the participant will repeat HBV DNA PCR testing every 3 months until the EOT. Note: For other countries in which there are hepatitis B screening guidelines, these can be done per local regulations or country standard of care.\n   3. Participant has positive results for HIV by serology, regardless of viral load.\n8. Other infectious diseases:\n\n   1. Participant has a history of active infection or febrile illness within 10 days prior to Day 1, as assessed by the investigator.\n   2. Participant has a history of symptoms suggestive of systemic or invasive infection within 30 days prior to Day 1.\n   3. Participant has a history of bacterial, viral, or fungal infection that required hospitalization or treatment with intravenous (IV) antimicrobial therapy within 8 weeks prior to Day 1, or oral antimicrobial therapy within 30 days prior to Day 1.\n   4. Participant has a history of chronic or recurrent bacterial disease, including but not limited to chronic pyelonephritis or cystitis, chronic bronchitis\u002Fpneumonitis, osteomyelitis, or chronic skin ulcerations (except those part of the HS clinical findings)\u002Finfections or fungal infections (except ungual onychomycosis).\n   5. Participant has a history of an infected joint prosthesis unless that prosthesis has been removed or replaced at least 60 days prior to Day 1.\n   6. Participant has a history of opportunistic infections (for example, Pneumocystis jirovecii pneumonia, histoplasmosis, or coccidiomycosis).\n   7. Participant had a bacterial infection within 60 days prior to Day 1 for which he or she did not receive treatment.\n\n   Noninfectious Disorders Exclusions:\n9. Participant has any clinically significant medical condition, evidence of an unstable clinical condition (for example, cardiovascular, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, neurologic, nutritional, ophthalmologic, or immunologic), or vital signs\u002Fphysical\u002Flaboratory\u002Felectrocardiogram (ECG) abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of trial results. These include but are not limited to:\n\n   1. Participant has a history of known or suspected condition\u002Fillness that is consistent with compromised immunity, including but not limited to any identified congenital or acquired immunodeficiency, splenectomy.\n   2. Participant has a history of new or unstable autoimmune disease (including but not limited to autoimmune thyroid disease, alopecia areata, lupus, Sjogren's, myasthenia gravis, or rheumatoid arthritis).\n   3. Participant had a major surgery within 60 days prior to Day 1 or has a major surgery planned during the trial.\n   4. Participant has unstable, poorly controlled, or severe hypertension at screening, confirmed by 2 repeat assessments.\n   5. Participant has a history of Class III or IV congestive heart failure as defined by New York Heart Association criteria.\n   6. Participant has a history of lymphoproliferative disease.\n   7. For participants with asthma, chronic obstructive pulmonary disease, or other pulmonary illnesses, participant has been hospitalized in the past 3 months, has ever required intubation for treatment, currently requires oral corticosteroids, or has required more than 1 course of oral corticosteroids within 6 months prior to Day 1.\n   8. Participant has any of the following cardiovascular disease history:\n\n      * A new diagnosis of atrial fibrillation or an episode of atrial fibrillation with rapid ventricular response or other dysrhythmia, nonacute cardiac hospitalization (for example, pacemaker implantation), pulmonary embolism, or deep venous thrombosis within the past 6 months prior to screening.\n      * Any history of cerebrovascular event, myocardial infarction, coronary stenting, or aortocoronary bypass surgery. If, however, the investigator documents there are no suitable treatment alternatives available for the participant and it has been at least 6 months since the occurrence of any such event, the participant may enroll; in the EU\u002FEEA, investigators must document a favorable benefit-risk assessment.\n   9. Participant has significant\u002Funcontrolled psychiatric illness, in the opinion of the investigator.\n   10. Participant has any lifetime history of suicide attempts, or active suicidal ideation or suicidal behavior in the past 5 years, or any diagnosis of severe depression or other unstable psychiatric condition in the last 6 months, based on: (1) medical history; or (2) Columbia-Suicide Severity Rating Scale (C-SSRS) documentation by answering \"yes\" to Question 4 or 5 for suicidal ideation concerning the previous 5 years before participation on the C-SSRS at screening or Day 1; or (3) is clinically deemed to have a suicide risk by the investigator, or in the opinion of the investigator, would pose an unacceptable risk to the participant's safety or impact their ability to comply with trial procedures.\n   11. Participant has a score of 15 or above at screening or Day 1 on the 8-item Patient Health Questionnaire-8 (PHQ-8).\n   12. Participant has a history of active substance abuse or a history of substance abuse within 12 months prior to screening.\n\n   Laboratory\u002FPhysical Exclusions:\n10. Participant has ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if they participated in the trial, in the opinion of the investigator.\n11. Participant has inadequate renal, hepatic, or pancreatic function before enrollment based on the following parameters:\n\n    1. Total bilirubin (unconjugated and\u002For conjugated) \\>1.5 × upper limit of the normal range (ULN) unless the participant has known Gilbert's syndrome that can explain the elevation of bilirubin, or\n    2. Serum alanine aminotransferase (ALT) or AST \\>3 × ULN, or\n    3. Creatinine \\>1.5 × ULN. Note: The participant may be retested (1 time) to meet eligibility criteria at the discretion of the investigator.\n    4. Estimated creatinine clearance lesser than (\\\u003C)45 milliliter per minute (mL\u002Fmin) based on the Cockcroft-Gault calculation.\n    5. A history of chronic pancreatitis or recent acute pancreatitis (\\\u003C60 days\u002Fnot fully resolved).\n12. Participant has any of the following laboratory values at the screening visit:\n\n    1. Hemoglobin \\\u003C9.0 gram per deciliter (g\u002FdL) (\\\u003C90.0 gram per liter \\[g\u002FL\\]).\n    2. Absolute white blood cell count \\\u003C3.0 × 10\\^9\u002FL (\\\u003C3000\u002F cubic millimeters \\[mm\\^3\\]).\n    3. Absolute neutrophil count (ANC) of \\\u003C1.0 × 10\\^9\u002FL (\\\u003C1000\u002Fmm\\^3).\n    4. Absolute lymphocyte count of \\\u003C0.5 × 10\\^9\u002FL (\\\u003C500\u002Fmm\\^3).\n    5. Platelet count \\\u003C100 × 10\\^9\u002FL (\\\u003C100,000\u002Fmm\\^3).\n    6. Thyroid-stimulating hormone (TSH) (\\>10 milli-international units per liter \\[mIU\u002FL\\]) or free T4 or T3 outside the normal reference range. Note: Participants would be allowed to rescreen after treatment.\n    7. Triglyceride level \\>=750 milligram per deciliter \\[mg\u002FdL\\] (\\>=8.5 millimole per liter \\[mmol\u002FL\\]).\n    8. Creatine phosphokinase (CPK) \\> ULN. CPK may be repeated once; if repeat value is Common Terminology Criteria for Adverse Events (National Cancer Institute) (CTCAE) Grade 1 or lower (or lesser than or equal to \\[\\\u003C=\\]2.5 × ULN) and no higher than the initial value, participant remains eligible. Investigators should assess the participant for modulating factors including concomitant medications or vigorous exercise that may affect CPK levels.\n    9. Participant has any other significant laboratory abnormalities that, in the opinion of the investigator, might place the participant at unacceptable risk for participation in this trial.\n    10. Participant does not tolerate venipuncture or inability to be venipunctured.\n\n    Allergies and Adverse Drug Reactions Exclusions:\n13. Participant has a history of significant drug allergy (such as anaphylaxis).\n14. Participant has a known or suspected allergy to zasocitinib or any of its components.\n\n    Other Exclusions:\n15. Participant has a positive pregnancy test result or plans to become pregnant during the trial period, including plans to donate ova (eggs) or sperm, or participant is pregnant or lactating\u002Fnursing.\n16. Participant has a history of substance abuse within 12 months prior to Day 1.\n17. Participants who have given greater than 500 mL of blood or plasma within 30 days prior to screening (during a clinical trial or at a blood bank donation) or plan to donate blood during the course of the trial.\n18. Participant is compulsorily detained for treatment of either a psychiatric or physical (for example, infectious disease) illness, or is committed to an institution (for example, prison) by virtue of an order issued either by judicial or administrative authorities.\n19. Participant is a trial site employee, an immediate family member (for example, spouse, parent, child, sibling), or is in a dependent relationship with trial site employee who is involved in the conduct of this trial or may consent under duress.\n20. In Germany, participant is incapable of giving consent or otherwise meets criteria in Sections 136 or 137 of the Verordnung zum Schutz vor der schädlichen Wirkung ionisierender Strahlung Strahlenschutzverordnung.\n21. Participants with a history of malignancy within the past 5 years prior to the screening visit are excluded, EXCEPT if the malignancy was a cutaneous squamous or basal cell carcinoma, or in situ cervical cancer that has been successfully treated and is considered cured; in the EU\u002FEEA, investigators must document a favorable benefit-risk assessment.\n22. History or current status of substance use disorder and or tobacco use disorder. For participants with excessive alcohol intake or currently smoking or using chewing tobacco or with a history of long-term smoking (\\>=20 pack years) or chewing tobacco use, the investigator must document a favorable benefit-risk assessment to justify the participant's inclusion in the trial.\n\nFurther exclusion criteria apply.",{"count":483,"type":22},90,[25],"Hidradenitis Suppurativa (HS) is a skin condition that causes deep, painful bumps on the skin. These bumps usually appear in an area where the skin rubs together. They start as small bumps but may become swollen and red over time. If they fill with pus, these lumps are called abscesses; these can also burst. Over time, the area can get scars and tunnels on or under the skin. Recent studies suggest that the condition may start when hair follicles become damaged and blocked. This impacts the skin and may activate the body's germ-fighting (immune) system. This allows bacteria to grow on the skin which worsens the condition and can cause abscesses.\n\nThe main aims of this study are to learn how safe zasocitinib is, how well it works and how well adults with HS tolerate it compared with a placebo.\n\nThe participants will receive the study treatment (either zasocitinib or placebo) for up to 4 months (16 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. After the first 4 months, all participants (also those who initially received placebo) will then receive zasocitinib for up to 8 months (36 weeks).\n\nDuring the study, participants will visit their study clinic 12 times.",[28],[488],"Drug Therapy","2026-03-05",{"date":491,"type":33},"2026-03-06",{"date":493,"type":33},"2026-01-26",{"date":495,"type":22},"2028-02-22",{"name":497,"class":40},"Takeda",49,{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":18,"minAge":506,"maxAge":50,"enrollmentInfo":507,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":180},"100611684","regulatory-post-marketing-surveillance-in-hidradenitis-suppurativa-pediatric-plaque-psoriasis-and-jia-treated-with-cosentyxsecukinumab-in-korea-100611684","NCT07243782","Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea","Regulatory Post-Marketing Surveillance to Assess Safety and Effectiveness in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea : a rPMS Study","Inclusion Criteria:\n\nHidradenitis suppurativa:\n\n1. Adults 18 years of age and older with moderate to severe hidradenitis suppurativa who are or will be receiving Cosentyx within the scope of approved indication.\n2. Patients who have agreed to participate in study (written informed consent)\n\nPediatric plaque psoriasis:\n\n1. Patients with moderate to severe plaque psoriasis between the ages of 6 and 18 years who are receiving or will receive Cosentyx within the scope of approved indication.\n2. Patients with patient or guardian consent to participate in study (written informed consent)\n\nJuvenile idiopathic arthritis:\n\n1. Enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category patients with enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category between the ages of 6 and 18 years and are receiving or will receive Cosentyx within the scope of approved indication.\n2. Patients with patient or guardian consent to participate in study (written informed consent)\n\nExclusion Criteria:\n\n1. Patients who are contraindicated according to national prescribing information\n2. Patients participating in other interventional clinical trials","6 Years",{"count":508,"type":22},76,"Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea",[28,511,512],"Pediatric Plaque Psoriasis","Juvenile Idiopathic Arthritis","2026-03-03",{"date":489,"type":33},{"date":516,"type":33},"2025-12-22",{"date":518,"type":22},"2027-06-15",{"name":68,"class":40},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":18,"minAge":393,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":23,"phases":530,"briefSummary":531,"conditions":532,"keywords":533,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":547},"100507576","phase-3-a-study-to-assess-change-in-disease-activity-and-adverse-events-of-oral-upadacitinib-in-adult-and-adolescent-participants-with-moderate-to-severe-hidradenitis-suppurativa-who-have-failed-anti-tnf-therapy-100507576","NCT05889182","A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy","A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy","Step-Up HS","Inclusion Criteria:\n\n* Diagnosis of hidradenitis suppurativa (HS) for at least 6 months prior to Baseline, as determined by the investigator (i.e., through medical history and interview of participant).\n* Documented history of previous use of \\>= 1 tumor necrosis factor (TNF) inhibitor for HS for at least 12 weeks and\u002For 1 approved non-anti-TNF biologic therapy for HS for at least 16 weeks characterized by inadequate response or for any duration characterized by intolerance as determined by the investigator.\n* Participant must have a total abscess and inflammatory nodule (AN) count of \\>= 5 at Baseline.\n* HS lesions must be present in at least 2 distinct anatomic areas at Baseline.\n* At least 1 anatomic area of HS involvement characterized as Hurley Stage II or higher at Baseline.\n* Draining fistula count of \\\u003C= 20 at Baseline.\n\nExclusion Criteria:\n\n* History of active skin disease other than HS that could interfere with the assessment of HS, including skin infections (bacterial, fungal, or viral) requiring systemic treatment within 4 weeks of the Baseline visit.\n* Treatment with any investigational drug of chemical or biologic nature within a minimum of 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug or be currently enrolled in another interventional clinical study. Investigational drugs are also prohibited during the study.\n* Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 (e.g., rituximab) within 12 months prior to Baseline or until B cell count returns to normal level or pre-treatment level.\n* Use of prescription topical therapies (including topical antibiotics) that can also be used to treat HS within 14 days prior to the Baseline visit.\n* Received any systemic (including oral) antibiotic treatment for HS or any other chronic inflammatory disorder within 14 days prior to the Baseline visit.",{"count":529,"type":22},1328,[80],"Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal\u002Fgenital) regions. This study will assess how safe and effective upadacitinib is in treating adult and adolescent participants with moderate to severe HS who have failed to respond to or are intolerant of anti-tumor necrosis factor (TNF) therapy. Adverse events and change in disease activity will be assessed.\n\nUpadacitinib is an approved drug for ulcerative colitis, atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of HS. This study is \"double-blinded\", meaning that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo. This study is comprised of 3 periods. In Period 1, participants are randomized into 2 groups called treatment arms where each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. In Period 2, participants are placed into 6 different groups depending on their placement and results in Period 1. Period 3 is the long-term extension period where participants will continue treatment from Period 2. Approximately 1328 adult and adolescent participants diagnosed with HS will be enrolled in approximately 300 sites worldwide.\n\nParticipants will receive oral tablets of upadacitinib or placebo once daily for 36 weeks in Period 1 and Period 2. Eligible participants from Period 1 and Period 2 will enter Period 3 and receive oral tablets of upadacitinib or placebo once daily for 68 weeks. Participants will be followed up for approximately 30 days.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular outpatient visits during the study. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.",[28],[28,534,535,536,537],"Upadacitinib","ABT-494","Rinvoq","STEP-UP HS","2026-03-02",{"date":540,"type":33},"2026-03-04",{"date":542,"type":33},"2023-06-21",{"date":544,"type":22},"2028-03",{"name":546,"class":40},"AbbVie",285,{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":155,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":180},"100297029","the-ohio-state-university-dermatology-biorepository-100297029","NCT03146676","The Ohio State University Dermatology Biorepository","Inclusion Criteria:\n\n* Seen by an Ohio State University (OSU) Dermatology provider on the main University Hospital campus, including the James Cancer Hospital, OSU Dermatology East, OSU Dermatology at the Ohio State Eye and Ear Institute, Martha Morehouse Medical Pavilion, and OSU Dermatology at Upper Arlington after the date of approval of this protocol\n* Ability to provide informed consent, or parent or legal guardian capable of providing consent for child or mentally handicapped individuals\n* Willingness to participate in a research study.\n\nExclusion Criteria:\n\n* Inability to provide informed consent",{"count":555,"type":22},175,"This study will create and extend a source of clinical specimens for the future study of inflammatory skin disorders.",[28],"2026-02-24",{"date":560,"type":33},"2026-02-27",{"date":562,"type":33},"2017-04-19",{"date":564,"type":22},"2030-12-31",{"name":566,"class":179},"Ohio State University",{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":573,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":575,"targetDuration":577,"studyType":53,"phases":4,"briefSummary":578,"conditions":579,"keywords":586,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":602},"100458003","myriad-augmented-soft-tissue-reconstruction-registry-100458003","NCT05243966","Myriad™ Augmented Soft Tissue Reconstruction Registry","Registry of Myriad™ Utilization in Soft Tissue Reconstruction Procedures","MASTRR","Inclusion Criteria:\n\n* Willing and able to provide written informed consent and to comply with the requirements of Clinical Investigational Plan\n* Male or female patients aged 18 years or above\n* Patients where Matrix and\u002For Morcells were used as part of their soft tissue reconstruction procedure\n* Subject that are willing and able to comply with all aspects of the treatment and evaluation schedule\n\nExclusion Criteria:\n\n* Patients with known sensitivity to ovine (sheep) derived material\n* Patients with full thickness ('third degree') burns\n* Patients with wounds with uncontrolled clinical infection (CDC Contamination Grade=4)\n* Any medical condition or serious intercurrent illness that, in the opinion of the investigator, may make it undesirable for the patient to participate in the study\n* Patient is currently participating or has participated in another clinical study within past 30 days prior to enrollment\n* Pregnant or lactating women\n* Any subject who, at the discretion of the Investigator, is not suitable for inclusion in the study",{"count":576,"type":22},800,"12 Months","This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures. The study will enroll participants who are undergoing a surgical procedure, where the attending physician will use Myriad™ as part of the surgical intervention.",[580,581,582,583,584,28,585],"Abdominal Wound Dehiscence","Necrotizing Soft Tissue Infection","Lower Extremity Wound","Pilonidal Sinus","Anal Fistula","Pressure Injury",[587,588,589,590,591,592],"Soft tissue reconstruction","Limb salvage","Extracellular matrix","Soft tissue reinforcement","Wound reconstruction","Regenerative medicine","2026-02-17",{"date":595,"type":33},"2026-02-19",{"date":597,"type":33},"2022-01-10",{"date":599,"type":22},"2029-01",{"name":601,"class":40},"Aroa Biosurgery Limited",13,{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":607,"acronym":4,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":609,"targetDuration":4,"studyType":23,"phases":611,"briefSummary":612,"conditions":613,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":180},"100520588","early-phase-1-capsule-microbiota-transplant-therapy-for-hidradenitis-suppurativa-100520588","NCT06058520","Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa","Inclusion Criteria:\n\n* Able and willing to provide informed consent\n* English speaking\n* Age \\>= 18years of age\n* Diagnosis of hidradenitis suppurativa by a dermatologist\n* Women who are not post-menopausal (at least 12 months of non-therapy induced amenorrhea) or surgically sterile (e.g. absence of ovaries and\u002For uterus) must remain abstinent or use a highly effective form of birth control (e.g. oral contraception, transdermal patch, barrier, intrauterine device). Periodic abstinence and early withdraw are not acceptable methods\n* Able to comply to study measures in the opinion of the investigator.\n* Stable doses of all medications for 30 days prior to baseline\n\nExclusion Criteria:\n\n* Non-English speaking\n* Refusal or inability to provide informed consent\n* Planning on moving within 6 months from start of study\n* Allergy to neomycin or vancomycin\n* Anaphylactic food allergies\n* Pregnancy, breastfeeding or planning pregnancy during study period (negative pregnancy test needed for persons of childbearing potential)\n* Use of any topical or oral antibiotics within 30 days of randomization\n* Use of any oral antibiotics within 90 days of randomization\n* History of inflammatory bowel disease\n* Extensive bowel resection (e.g., subtotal colectomy, substantial removal of small bowel)\n* No major bowel surgery within 4 weeks prior to baseline or planned major surgery during the study period\n* No active skin disease other than HS that could interfere with assessments",{"count":610,"type":22},16,[191],"HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or atopic dermatitis (AD). HS also has a large economic impact, due to frequent emergency department and inpatient care utilization, and re-hospitalization rates similar to congestive heart failure. Unfortunately, few treatment options are effective. There are currently three FDA-approved treatments for HS, including adalimumab, secukinumab, and bimekizumab, each with only 40- 60% respond to treatment and over 50% lose response within one year . The overarching goal of this pilot study is to investigate the central hypothesis that oral microbiota transplant therapy(MTT) alters the gut microbiome in patients with Hidradenitis Suppurativa (HS), influencing cutaneous microbiota via systemically absorbed gut-derived metabolites.",[28],"2026-02-13",{"date":593,"type":33},{"date":617,"type":33},"2023-10-01",{"date":619,"type":22},"2026-09-01",{"name":621,"class":179},"University of Minnesota"]